In a nation that spends nearly double the resources of its peers on health care, we recognize the urgency for innovative solutions to reshape health care delivery and expenditure in the United States. We're committed to unraveling the intricate connections between insurance design, market structures, and policy dynamics to pave the way for enhanced patient outcomes and reduced spending.
Center for Advancing Health Policy through Research
Center for Advancing Health Policy through Research
We work to understand health care affordability and value to translate research into policy change.
Center for Advancing Health Policy through Research
We work to understand health care affordability and value to translate research into policy change.
Is Private Equity Ruining Health Care? It's Complicated
Is private equity good AND bad? Listen to experts including Dr. Yashaswini Singh talk about private equity with a nuanced approach.
The Center for Advancing Health Policy through Research (CAHPR) seeks to make fundamental contributions towards understanding and developing policies that increase affordability and value in U.S. healthcare.
The Top-Ten Health Affairs Forefront Articles Of 2023
Dr. Chris Whaley's 2023 publication along with other colleagues "What’s Behind Losses At Large Nonprofit Health Systems? " gets recognized as one of the top ten most read Health Affairs Forefront articles in 2023.
Recent CAHPR in the Media
See all CAHPR in the media Christopher Whaley, testified before Congress, highlighting the urgent need of health care price transparency and its role in combating high healthcare costs in the US and enhancing policy decision-making.
Medicare payment parity key to saving independent physicians, Dr. Ashish Jha tells Congress
Dr. Ashish K. Jha, dean of the Brown University School of Public Health, addressed the House Committee on Ways and Means on why the U.S. is seeing a decline in private medical practices and what we can do about it.
Private equity escapes FTC in court, but anesthesia group doesn’t
The PE firm, Welsh, Carson, Anderson & Stowe has been released from the ongoing case against U.S. Anesthesia Partners, for monopolization in Texas. What does this mean for PE firms and antitrust scrutiny?